BC
ELV icon

Burleson & Co’s Elevance Health ELV Stock Holding History

Burleson & Co’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$649 Hold
1
– – ﹤0.01% 371
2022
Q3 		$1K Sell
1
-4
-80% -$1.91K ﹤0.01% 363
2022
Q2 		$3K Hold
5
– – ﹤0.01% 315
2022
Q1 		$3K Sell
5
-100
-95% -$45.7K ﹤0.01% 320
2021
Q4 		$49K Hold
105
– – 0.01% 196
2021
Q3 		$39K Buy
105
+1
+1% +$380 0.01% 204
2021
Q2 		$40K Hold
104
– – 0.01% 207
2021
Q1 		$37K Buy
+104
New +$33.4K 0.01% 197

Other funds holding ELV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Burleson & Co's ELV Position: Q4 2022 in Review

Burleson & Co held its Elevance Health (ELV) position steady in Q4 2022 at 1 share worth $649. The position accounts for ﹤0.01% of the portfolio, ranked #371.

Burleson & Co first reported a position in ELV in Q1 2021 and has held it in 8 quarters since. The position peaked at $49K in Q4 2021. 1,549 funds tracked by Wall St. Rank hold ELV as of Q4 2022.

  • Burleson & Co held 1 share of Elevance Health worth $649 as of Q4 2022.
  • Burleson & Co left its Elevance Health share count unchanged in Q4 2022.
  • Elevance Health made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #371 holding.
  • Burleson & Co first reported a position in Elevance Health in Q1 2021 and has held it in 8 quarters since.
  • Burleson & Co's Elevance Health position peaked at $49K in Q4 2021.
  • 1,549 funds tracked by Wall St. Rank held Elevance Health as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.